Posted on 07/02/2024 9:33:41 PM PDT by ConservativeMind
For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for resolution of MASH, according to a study.
Rohit Loomba, M.D. and colleagues conducted a phase 2, dose-finding, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive 52 weeks of 5-, 10-, or 15-mg once-weekly subcutaneous tirzepatide or placebo.
Overall, 157 of 190 participants who had undergone randomization had liver-biopsy results at week 52 that could be evaluated, with missing values imputed. The researchers found that the percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10, 44, 56, and 62 in the placebo and 5-, 10-, and 15-mg tirzepatide groups, respectively.
The percentage of patients who had an improvement of at least one fibrosis stage without worsening of MASH was 30 in the placebo group and 55, 51, and 51 in the 5-, 10-, and 15-mg tirzepatide groups, respectively. Gastrointestinal events were the most common adverse events reported in the tirzepatide groups and were mostly mild or moderate in severity.
(Excerpt) Read more at medicalxpress.com ...
Interestingly, the lowest dose, 5 mg, provided the best fibrosis improvement success.
I got over MASH when Alan Alda started getting all preachy.
CC
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.